Anti-inflammatory drugs are lacking in chronic obstructive pulmonary disease (COPD) and
inhibitors of the phosphodiesterase type-4 (PDE4) enzyme have been suggested to be an …

Chronic obstructive pulmonary disease represents a major global health care burden for
both primary and secondary care providers and is the most common respiratory condition …

Phosphodiesterases (PDEs) are responsible for the breakdown of intracellular cyclic
nucleotides, from which PDE4 are the major cyclic AMP metabolizing isoenzymes found in …

Phosphodiesterase 4 (PDE4) is a member of the PDE enzyme superfamily that inactivates
cyclic adenosine monophosphate and cyclic guanosine monophosphate, and is the main …

Phosphodiesterases hydrolyse intracellular cyclic nucleotides, cyclic adenosine
monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) into inactive 5 …

Phosphodiesterase 4 (PDE4) is a key cAMP-metabolizing enzyme involved in the
pathogenesis of inflammatory disease, and its pharmacological inhibition has been shown …

Xanthines like theophylline have long been recognised as being effective drugs for the
treatment of asthma and chronic obstructive pulmonary disease (COPD). They are of interest …

Publisher Summary This chapter focuses on phosphodiesterase-4 (PDE4) enzyme inhibitors
and their potential therapeutic utility. The chapter presents the in vitro pharmacology of …

Chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD) and
asthma, affect millions of people all over the world. Cyclic adenosine monophosphate …

Background Pulmonary fibrosis (PF) is a group of devastating and largely irreversible
diseases. Phosphodiesterase (PDE) 4 is involved in the processes of remodeling and …